{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:04Z","timestamp":1784764804547,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00228-024-03722-5","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T22:01:37Z","timestamp":1720216897000},"page":"1471-1482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["RETRACTED ARTICLE: Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"80","author":[{"given":"Omar","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Albdour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameen","family":"Alsaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"key":"3722_CR1","unstructured":"Tardive dyskinesia: what it is, causes, symptoms & treatment. Cleveland Clinic. Accessed 5 July 2023. https:\/\/my.clevelandclinic.org\/health\/articles\/6125-tardive-dyskinesia"},{"key":"3722_CR2","unstructured":"https:\/\/www.facebook.com\/WebMD. What is tardive dyskinesia? WebMD. Accessed 5 July\u00a0 2023. https:\/\/www.webmd.com\/mental-health\/tardive-dyskinesia"},{"key":"3722_CR3","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. Fifth Edition. American Psychiatric Association. https:\/\/doi.org\/10.1176\/appi.books.9780890425596","DOI":"10.1176\/appi.books.9780890425596"},{"key":"3722_CR4","unstructured":"Tardive dyskinesia. Mental Health America. Accessed 5 July 2023. https:\/\/mhanational.org\/conditions\/tardive-dyskinesia"},{"issue":"6","key":"3722_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0706743719828968","volume":"64","author":"L Ricciardi","year":"2019","unstructured":"Ricciardi L, Pringsheim T, Barnes TRE et al (2019) Treatment recommendations for tardive dyskinesia. Can J Psychiatry Rev Can Psychiatr 64(6):388\u2013399. https:\/\/doi.org\/10.1177\/0706743719828968","journal-title":"Can J Psychiatry Rev Can Psychiatr"},{"key":"3722_CR6","unstructured":"Mental illness. National Institute of Mental Health (NIMH). Accessed July 5, 2023. https:\/\/www.nimh.nih.gov\/health\/statistics\/mental-illness"},{"issue":"9","key":"3722_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM et al (2020) The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 177(9):868\u2013872. https:\/\/doi.org\/10.1176\/appi.ajp.2020.177901","journal-title":"Am J Psychiatry"},{"issue":"11","key":"3722_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"3722_CR9","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v106.i02","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A et al (2023) netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. https:\/\/doi.org\/10.18637\/jss.v106.i02","journal-title":"J Stat Softw"},{"issue":"4","key":"3722_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00004850-199707000-00003","volume":"12","author":"T Hayashi","year":"1997","unstructured":"Hayashi T, Yokota N, Takahashi T et al (1997) Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol 12(4):199\u2013205. https:\/\/doi.org\/10.1097\/00004850-199707000-00003","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"3722_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF00432517","volume":"87","author":"WM Glazer","year":"1985","unstructured":"Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M (1985) The treatment of tardive dyskinesia with baclofen. Psychopharmacology 87(4):480\u2013483. https:\/\/doi.org\/10.1007\/BF00432517","journal-title":"Psychopharmacology"},{"issue":"6","key":"3722_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1176\/ajp.151.6.925","volume":"151","author":"LM Dabiri","year":"1994","unstructured":"Dabiri LM, Pasta D, Darby JK, Mosbacher D (1994) Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 151(6):925\u2013926. https:\/\/doi.org\/10.1176\/ajp.151.6.925","journal-title":"Am J Psychiatry"},{"issue":"1","key":"3722_CR13","doi-asserted-by":"publisher","first-page":"18m12278","DOI":"10.4088\/JCP.18m12278","volume":"80","author":"CU Correll","year":"2018","unstructured":"Correll CU, Cutler AJ, Kane JM, McEvoy JP, Liang GS, O\u2019Brien CF (2018) Characterizing treatment effects of valbenazine for tardive dyskinesia: additional results from the KINECT 3 study. J Clin Psychiatry 80(1):18m12278. https:\/\/doi.org\/10.4088\/JCP.18m12278","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"3722_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0165-1781(92)90127-o","volume":"43","author":"T Kojima","year":"1992","unstructured":"Kojima T, Yamauchi T, Miyasaka M et al (1992) Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study. Psychiatry Res 43(2):129\u2013136. https:\/\/doi.org\/10.1016\/0165-1781(92)90127-o","journal-title":"Psychiatry Res"},{"issue":"9","key":"3722_CR15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/archpsyc.56.9.836","volume":"56","author":"LA Adler","year":"1999","unstructured":"Adler LA, Rotrosen J, Edson R et al (1999) Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 56(9):836\u2013841. https:\/\/doi.org\/10.1001\/archpsyc.56.9.836","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"3722_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/0006-3223(93)90119-x","volume":"33","author":"DC Goff","year":"1993","unstructured":"Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA (1993) A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 33(10):700\u2013706. https:\/\/doi.org\/10.1016\/0006-3223(93)90119-x","journal-title":"Biol Psychiatry"},{"issue":"12","key":"3722_CR17","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/s0006-3223(97)00027-9","volume":"43","author":"LA Adler","year":"1998","unstructured":"Adler LA, Edson R, Lavori P et al (1998) Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 43(12):868\u2013872. https:\/\/doi.org\/10.1016\/s0006-3223(97)00027-9","journal-title":"Biol Psychiatry"},{"issue":"1","key":"3722_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/01.jcp.0000104912.75206.2b","volume":"24","author":"XY Zhang","year":"2004","unstructured":"Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen DC, Wu GY (2004) The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol 24(1):83\u201386. https:\/\/doi.org\/10.1097\/01.jcp.0000104912.75206.2b","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"3722_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000116678","volume":"31","author":"J Mouret","year":"1991","unstructured":"Mouret J, Khomais M, Lemoine P, Sebert P (1991) Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture? Eur Neurol 31(4):199\u2013203. https:\/\/doi.org\/10.1159\/000116678","journal-title":"Eur Neurol"},{"issue":"3","key":"3722_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0306-4530(85)90011-3","volume":"10","author":"WM Glazer","year":"1985","unstructured":"Glazer WM, Naftolin F, Morgenstern H, Barnea ER, MacLusky NJ, Brenner LM (1985) Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology 10(3):345\u2013350. https:\/\/doi.org\/10.1016\/0306-4530(85)90011-3","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"3722_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00004714-198902000-00008","volume":"9","author":"JI Ludatscher","year":"1989","unstructured":"Ludatscher JI (1989) Stable remission of tardive dyskinesia by L-dopa. J Clin Psychopharmacol 9(1):39\u201341","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"3722_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00492207","volume":"65","author":"C de Montigny","year":"1979","unstructured":"de Montigny C, Chouinard G, Annable L (1979) Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology 65(3):219\u2013223. https:\/\/doi.org\/10.1007\/BF00492207","journal-title":"Psychopharmacology"},{"issue":"3","key":"3722_CR23","first-page":"252","volume":"52","author":"F Castro","year":"2011","unstructured":"Castro F, Carrizo E, de Prieto Rinc\u00f3n D et al (2011) Effectiveness of melatonin in tardive dyskinesia. Invest Clin 52(3):252\u2013260","journal-title":"Invest Clin"},{"issue":"1","key":"3722_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3109\/00048678109159413","volume":"15","author":"J George","year":"1981","unstructured":"George J, Pridmore S, Aldous D (1981) Double blind controlled trial of deanol in tardive dyskinesia. Aust N Z J Psychiatry 15(1):68\u201371. https:\/\/doi.org\/10.3109\/00048678109159413","journal-title":"Aust N Z J Psychiatry"},{"issue":"5\u20136","key":"3722_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0920-9964(90)90016-z","volume":"3","author":"WM Glazer","year":"1990","unstructured":"Glazer WM, Hafez H (1990) A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res 3(5\u20136):315\u2013320. https:\/\/doi.org\/10.1016\/0920-9964(90)90016-z","journal-title":"Schizophr Res"},{"issue":"4","key":"3722_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/0278-5846(88)90112-1","volume":"12","author":"T Matsunaga","year":"1988","unstructured":"Matsunaga T, Ohyama S, Takehara S et al (1988) The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 12(4):533\u2013539. https:\/\/doi.org\/10.1016\/0278-5846(88)90112-1","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"3722_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/089198879400700408","volume":"7","author":"BR Sommer","year":"1994","unstructured":"Sommer BR, Cohen BM, Satlin A, Cole JO, Jandorf L, Dorsey F (1994) Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo. J Geriatr Psychiatry Neurol 7(4):234\u2013237. https:\/\/doi.org\/10.1177\/089198879400700408","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"1","key":"3722_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00433006","volume":"79","author":"J Hajioff","year":"1983","unstructured":"Hajioff J, Wallace M (1983) Effect of Co-dergocrine mesylate on tardive dyskinesia. A preliminary report Psychopharmacology (Berl) 79(1):1\u20133. https:\/\/doi.org\/10.1007\/BF00433006","journal-title":"A preliminary report Psychopharmacology (Berl)"},{"issue":"5","key":"3722_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1600-0447.1986.tb06267.x","volume":"74","author":"SD Soni","year":"1986","unstructured":"Soni SD, Freeman HL, Bamrah JS, Sampath G (1986) Oxypertine in tardive dyskinesia: a long-term controlled study. Acta Psychiatr Scand 74(5):446\u2013450. https:\/\/doi.org\/10.1111\/j.1600-0447.1986.tb06267.x","journal-title":"Acta Psychiatr Scand"},{"key":"3722_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1192\/bjp.144.1.48","volume":"144","author":"SD Soni","year":"1984","unstructured":"Soni SD, Freeman HL, Hussein EM (1984) Oxypertine in tardive dyskinesia: an 8-week controlled study. Br J Psychiatry J Ment Sci 144:48\u201352. https:\/\/doi.org\/10.1192\/bjp.144.1.48","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"7","key":"3722_CR31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1176\/ajp.143.7.912","volume":"143","author":"A Wolkin","year":"1986","unstructured":"Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J (1986) Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry 143(7):912\u2013914. https:\/\/doi.org\/10.1176\/ajp.143.7.912","journal-title":"Am J Psychiatry"},{"issue":"12","key":"3722_CR32","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/mds.26330","volume":"30","author":"CF O\u2019Brien","year":"2015","unstructured":"O\u2019Brien CF, Jimenez R, Hauser RA et al (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord Off J Mov Disord Soc 30(12):1681\u20131687. https:\/\/doi.org\/10.1002\/mds.26330","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"4 Suppl","key":"3722_CR33","first-page":"49S","volume":"8","author":"GM Simpson","year":"1988","unstructured":"Simpson GM, Yadalam KG, Stephanos MJ (1988) Double-blind carbidopa\/levodopa and placebo study in tardive dyskinesia. J Clin Psychopharmacol 8(4 Suppl):49S-51S","journal-title":"J Clin Psychopharmacol"},{"key":"3722_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1192\/bjp.150.4.542","volume":"150","author":"GG Fisk","year":"1987","unstructured":"Fisk GG, York SM (1987) The effect of sodium valproate on tardive dyskinesia\u2013revisited. Br J Psychiatry J Ment Sci 150:542\u2013546. https:\/\/doi.org\/10.1192\/bjp.150.4.542","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"11","key":"3722_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/pcn.13455","volume":"76","author":"J Horiguchi","year":"2022","unstructured":"Horiguchi J, Watanabe K, Kondo K et al (2022) Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: a multicenter, randomized, double-blind, placebo-controlled study (J-KINECT). Psychiatry Clin Neurosci 76(11):560\u2013569. https:\/\/doi.org\/10.1111\/pcn.13455","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"3722_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.schres.2006.03.023","volume":"84","author":"R Emsley","year":"2006","unstructured":"Emsley R, Niehaus DJH, Koen L et al (2006) The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res 84(1):112\u2013120. https:\/\/doi.org\/10.1016\/j.schres.2006.03.023","journal-title":"Schizophr Res"},{"issue":"21","key":"3722_CR37","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","volume":"88","author":"HH Fernandez","year":"2017","unstructured":"Fernandez HH, Factor SA, Hauser RA et al (2017) Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology 88(21):2003\u20132010. https:\/\/doi.org\/10.1212\/WNL.0000000000003960","journal-title":"Neurology"},{"issue":"10","key":"3722_CR38","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1001\/archpsyc.1989.01810100050009","volume":"46","author":"JA Lieberman","year":"1989","unstructured":"Lieberman JA, Alvir J, Mukherjee S, Kane JM (1989) Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Arch Gen Psychiatry 46(10):908\u2013913. https:\/\/doi.org\/10.1001\/archpsyc.1989.01810100050009","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"3722_CR39","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","volume":"150","author":"LA Adler","year":"1993","unstructured":"Adler LA, Peselow E, Rotrosen J et al (1993) Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 150(9):1405\u20131407. https:\/\/doi.org\/10.1176\/ajp.150.9.1405","journal-title":"Am J Psychiatry"},{"issue":"8","key":"3722_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","volume":"4","author":"KE Anderson","year":"2017","unstructured":"Anderson KE, Stamler D, Davis MD et al (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 4(8):595\u2013604. https:\/\/doi.org\/10.1016\/S2215-0366(17)30236-5","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"3722_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF00426466","volume":"73","author":"CC Huang","year":"1981","unstructured":"Huang CC, Wang RI, Hasegawa A, Alverno L (1981) Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacology 73(4):359\u2013362. https:\/\/doi.org\/10.1007\/BF00426466","journal-title":"Psychopharmacology"},{"issue":"3","key":"3722_CR42","first-page":"124","volume":"39","author":"S Akhtar","year":"1993","unstructured":"Akhtar S, Jajor TR, Kumar S (1993) Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med 39(3):124\u2013126","journal-title":"J Postgrad Med"},{"issue":"8","key":"3722_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.4088\/jcp.v61n0803","volume":"61","author":"E Shamir","year":"2000","unstructured":"Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A (2000) Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry 61(8):556\u2013558. https:\/\/doi.org\/10.4088\/jcp.v61n0803","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"3722_CR44","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/archpsyc.58.11.1049","volume":"58","author":"E Shamir","year":"2001","unstructured":"Shamir E, Barak Y, Shalman I et al (2001) Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 58(11):1049\u20131052. https:\/\/doi.org\/10.1001\/archpsyc.58.11.1049","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"3722_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3928\/02793695-20110602-02","volume":"49","author":"RH Howland","year":"2011","unstructured":"Howland RH (2011) Drug therapies for tardive dyskinesia: part 2. J Psychosoc Nurs Ment Health Serv 49(7):17\u201320. https:\/\/doi.org\/10.3928\/02793695-20110602-02","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"issue":"6","key":"3722_CR46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/cap.2010.0145","volume":"21","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Lam D, Patten SB (2011) The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005\u20132009. J Child Adolesc Psychopharmacol 21(6):537\u2013543. https:\/\/doi.org\/10.1089\/cap.2010.0145","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"3722_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010861","volume":"6","author":"D Duncan","year":"2016","unstructured":"Duncan D, Cooke L, Symonds C, Gardner D, Pringsheim T (2016) Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open 6(3):e010861. https:\/\/doi.org\/10.1136\/bmjopen-2015-010861","journal-title":"BMJ Open"},{"issue":"3","key":"3722_CR48","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh CH, Kane JM, Correll CU (2017) Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 78(3):e264\u2013e278. https:\/\/doi.org\/10.4088\/JCP.16r10832","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"3722_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11940-009-0019-3","volume":"11","author":"F Susatia","year":"2009","unstructured":"Susatia F, Fernandez HH (2009) Drug-induced parkinsonism. Curr Treat Options Neurol 11(3):162\u2013169. https:\/\/doi.org\/10.1007\/s11940-009-0019-3","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"3722_CR50","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2217\/cer-2017-0065","volume":"7","author":"SN Caroff","year":"2018","unstructured":"Caroff SN, Aggarwal S, Yonan C (2018) Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. J Comp Eff Res 7(2):135\u2013148. https:\/\/doi.org\/10.2217\/cer-2017-0065","journal-title":"J Comp Eff Res"},{"key":"3722_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209.pub2","author":"K Soares-Weiser","year":"2011","unstructured":"Soares-Weiser K, Maayan N, McGrath J (2011) Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD000209.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3722_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/2046-4053-1-60","volume":"1","author":"L Turner","year":"2012","unstructured":"Turner L, Shamseer L, Altman DG, Schulz KF, Moher D (2012) Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane reviewa. Syst Rev 1(1):60. https:\/\/doi.org\/10.1186\/2046-4053-1-60","journal-title":"Syst Rev"},{"key":"3722_CR53","doi-asserted-by":"publisher","unstructured":"Tammenmaa\u2010Aho I, Asher R, Soares\u2010Weiser K, Bergman H (2018) Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev (3). https:\/\/doi.org\/10.1002\/14651858.CD000207.pub2","DOI":"10.1002\/14651858.CD000207.pub2"},{"issue":"3","key":"3722_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jagp.2021.08.003","volume":"30","author":"M Sajatovic","year":"2022","unstructured":"Sajatovic M, Finkbeiner S, Wilhelm A et al (2022) Long-term safety and efficacy of deutetrabenazine in younger and older patients with tardive dyskinesia. Am J Geriatr Psychiatry 30(3):360\u2013371. https:\/\/doi.org\/10.1016\/j.jagp.2021.08.003","journal-title":"Am J Geriatr Psychiatry"},{"key":"3722_CR55","doi-asserted-by":"publisher","first-page":"773999","DOI":"10.3389\/fneur.2022.773999","volume":"13","author":"RA Hauser","year":"2022","unstructured":"Hauser RA, Barkay H, Fernandez HH et al (2022) Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol 13:773999. https:\/\/doi.org\/10.3389\/fneur.2022.773999","journal-title":"Front Neurol"}],"updated-by":[{"DOI":"10.1007\/s00228-025-03923-6","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000}},{"DOI":"10.1007\/s00228-025-03923-6","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"record-id":"71716"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03722-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:28:27Z","timestamp":1769092107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03722-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3722"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03722-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,6]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00228-025-03923-6","URL":"https:\/\/doi.org\/10.1007\/s00228-025-03923-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}